



Express Mail No. EV 452 776 759 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Satoh et al. Confirmation No.: 6771
Application No.: 10/004,645 Group Art Unit: 1617
Filed: December 4, 2001 Examiner: Kim, Jennifer M.
For: ANILINOPYRIMIDINE Attorney Docket No.: 10624-050-999
DERIVATIVES AS JNK CAM: 700755-999049
INHIBITORS AND
COMPOSITIONS AND
METHODS RELATED THERETO

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321(c)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Signal Pharmaceuticals, LLC is the assignee of the entire right, title and interest in and to U.S. App. 10/004,642 (the “‘642 application”) by virtue of an assignment from the inventors to Signal Pharmaceuticals, Inc. recorded in the United States Patent and Trademark Office (“USPTO”) on August 13, 2002 at Reel 013201 / Frame 0022, and a conversion from “Inc.” to “LLC” recorded in the USPTO on January 14, 2005 at Reel 016440 / Frame 0675.

Signal Pharmaceuticals, LLC is also the assignee of the entire right, title and interest in and to the above-identified application by virtue of an assignment from the inventors to Signal Pharmaceuticals, Inc. recorded in the United States Patent and Trademark Office USPTO on July 23, 2002 at Reel 013125 / Frame 0689, and a conversion from “Inc.” to “LLC” recorded in the USPTO on January 14, 2005 at Reel 016154 / Frame 0737.

Signal Pharmaceuticals, LLC hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of a patent issuing from the ‘642 application, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and

02/16/2006 EFLORES 00000121 503013 10004645

01 FC:1814

130.00 DA

during such period that the legal title to said patent shall be the same as the legal title to a patent issuing from the '642 application.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration of the full statutory term of a patent issuing from the '642 application in the event that such patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

A fee of \$ 110.00 is believed due under 37 C.F.R. 120(d) for the submission of this terminal disclaimer. Please charge this, and any other required fees, to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Date: February 13, 2006

Respectfully submitted,
By: Anthony M. Insogna, Reg. No. 35,203
Mitchell J. Bruney, Reg. No. 47,458
Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130